(Q35720929)

9 August 2017

title

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues (English)

1 reference

9 August 2017

20

Jonathan Uhr

1 reference

9 August 2017

17

Leon W M M Terstappen

1 reference

9 August 2017

16

Dorothee Herlyn

1 reference

9 August 2017

Songdong Meng

1

1 reference

9 August 2017

Debu Tripathy

2

1 reference

9 August 2017

Sanjay Shete

3

1 reference

9 August 2017

Raheela Ashfaq

4

1 reference

9 August 2017

Hossein Saboorian

5

1 reference

9 August 2017

Barbara Haley

6

1 reference

9 August 2017

Eugene Frenkel

7

1 reference

9 August 2017

David Euhus

8

1 reference

9 August 2017

Marilyn Leitch

9

1 reference

9 August 2017

Cynthia Osborne

10

1 reference

9 August 2017

Edward Clifford

11

1 reference

9 August 2017

Steve Perkins

12

1 reference

9 August 2017

Peter Beitsch

13

1 reference

9 August 2017

Amanullah Khan

14

1 reference

9 August 2017

Larry Morrison

15

1 reference

9 August 2017

Jianqiang Wang

19

1 reference

9 August 2017

Nancy Lane

18

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

9 August 2017

number of pages

5

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

9 August 2017

volume

103

1 reference

9 August 2017

issue

46

1 reference

9 August 2017

page(s)

17361-17365

1 reference

Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Epidermal growth factor receptor (EGFR) signaling in cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Prognostic and predictive factors revisited

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Urokinase-type plasminogen activator system and breast cancer (Review).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

HER-2/neu evaluation in breast cancer are we there yet?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

HER-2/neu testing in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

The urokinase receptor as a potential target in cancer therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

HER-2 gene amplification can be acquired as breast cancer progresses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Targeted therapy in breast cancer: the HER-2/neu gene and protein

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.

12 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0608113103

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0608113103

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0608113103

Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1838539

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study

25 September 2018

1 reference

12 December 2020

Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells

1 reference

12 December 2020

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

12 December 2020

Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer

1 reference

12 December 2020

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

12 December 2020

Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer

1 reference

12 December 2020

Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

1 reference

12 December 2020

Circulating tumor cells in patients with breast cancer dormancy

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0608113103

1 reference

9 August 2017

0 references

1 reference

9 August 2017

1 reference